Hikma Pharmaceuticals Public annual return on equity
2021
2022
2023
2024
2025
Hikma Pharmaceuticals Public Return on Equity (ROE) Growth & History (HIK)
Hikma Pharmaceuticals Public's return on equity was 16.60% for fiscal 2025.
View full Hikma Pharmaceuticals Public company overviewHikma Pharmaceuticals Public annual return on equity history
| Fiscal year | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | 16.60% | +0.54 pp |
| 2024 | 2024-12-31 | 16.06% | +7.20 pp |
| 2023 | 2023-12-31 | 8.86% | +0.54 pp |
| 2022 | 2022-12-31 | 8.33% | −9.98 pp |
| 2021 | 2021-12-31 | 18.31% | — |
Hikma Pharmaceuticals Public return on equity trends
Between the periods ended 2021-12-31 and 2025-12-31, Hikma Pharmaceuticals Public's return on equity decreased from 18.31% to 16.60%, a change of −1.71 percentage points.
About the metric
What return on equity (ROE) means
Return on equity (ROE) measures how much net income a company generates relative to shareholders’ equity. It can help evaluate how efficiently equity capital is used, but unusually high or negative values may reflect leverage, losses, or a small equity base.
Calculation and source
How return on equity is calculated
TickerStat calculates ROE as reported net income divided by average stockholders’ equity at the beginning and end of the fiscal period. Periods with missing or non-positive average equity are omitted. Quarterly ROE uses quarterly net income and is not annualized. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Hikma Pharmaceuticals Public source filings ↗Community posts
Hikma’s epinephrine nasal spray advances into regulatory review
Hikma ($HIK) said regulators in the United States, Europe and the UK have accepted submissions for its investigational epinephrine nasal spray for review. The company has also filed in Canada and intends to expand submissions to additional ...